The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Cytogenetic analysis from the PERSEUS trial of Dara-VRd in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses a cytogenetic analysis from the PERSEUS trial (NCT03710603), which investigated the addition of daratumumab (Dara) to bortezomib, lenalidomide, and dexamethasone (VRd) in multiple myeloma. This study showed that in all sub-groups of patients, there was an advantage regarding progression-free survival (PFS) and depth of response in favor of Dara-VRd compared to the control arm. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
